Correction to: Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (Current Oncology, (2023), 30, 7, (6097-6110), 10.3390/curroncol30070454)

In the original publication [1], there was a mistake in Table 2 as published. The original Table 2 considered different amounts of patients for the survival analysis at the data cut-off. The corrected Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. © 2024 by the authors.

Correction to: Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (Current Oncology, (2023), 30, 7, (6097-6110), 10.3390/curroncol30070454) Academic Article in Scopus